logo
ProjectOngoing

Targeting the Oncogenic hEag1 Ion Channel: Developing Venom Peptide-Based Pharmacological Tools

The status, timeline and source of this project. A free account opens every field.

Source: EU Funding & Tenders Portal

The human ether à go-go 1 (hEag1) ion channel, also known as Kv10.1, is a voltage-gated potassium channel that is highly expressed in the brain but remains largely absent in other tissues under healthy conditions. However, during cancer development, hEag1 is significantly upregulated in various tumours, making it a potential biomarker and therapeutic target. Its role in cancer, particularly in bre

Status
Under Construction
Sector
Commercial
Location
Austria
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about Targeting the Oncogenic hEag1 Ion Channel: Developing Venom Peptide-Based Pharmacological Tools

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “Targeting the Oncogenic hEag1 Ion Channel: Developing Venom Peptide-Based Pharmacological Tools” is an infrastructure initiative in the Commercial sector, located in Austria. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Not available for this record.

Status

Original status

ongoing

Taiyo status

Under Construction

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

The human ether à go-go 1 (hEag1) ion channel, also known as Kv10.1, is a voltage-gated potassium channel that is highly expressed in the brain but remains largely absent in other tissues under healthy conditions. However, during cancer development, hEag1 is significantly upregulated in various tumours, making it a potential biomarker and therapeutic target. Its role in cancer, particularly in breast cancer, is still not well understood, which makes exploring hEag1 a critical focus of my research. In this project, I aim to discover and develop the first series of selective hEag1 ligands that can be used as pharmacological probes and therapeutic leads to investigate the channel's function in breast cancer. Building on preliminary data, I will utilize the rich pharmacological diversity found in animal venoms to identify novel peptide ligands that target hEag1. Through structure-activity relationship (SAR) studies and advanced medicinal chemistry, I plan to enhance the potency and selectivity of both newly discovered and existing ligands. These optimized compounds will enable me to explore the functional role of hEag1 in breast cancer progression and assess its therapeutic potential. By integrating peptide chemistry, pharmacology, and preclinical methodologies, this research will pave the way for the creation of highly specific hEag1-targeting probes and drugs. The ultimate goal is to deepen our understanding of hEag1's role in breast cancer and unlock new avenues for targeted cancer therapy, especially for aggressive forms like triple-negative breast cancer.

Location

Country

Austria

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Sector

Commercial

Article published date

2026-01-01

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project